Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

IGC Pharma, Inc. Common Stock (NY:IGC)

0.2993 +0.0071 (+2.43%)
Official Closing Price Updated: 8:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 248,832
Open 0.2922
Bid (Size) 0.2982 (7)
Ask (Size) 0.3090 (30)
Prev. Close 0.2922
Today's Range 0.2922 - 0.3069
52wk Range 0.2525 - 0.5800
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting
Via ACCESS Newswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga

Performance

YTD
-16.2%
-16.2%
1 Month
+5.6%
+5.6%
3 Month
-1.9%
-1.9%
6 Month
-14.7%
-14.7%
1 Year
-44.5%
-44.5%

More News

Read More
IGC Pharma Welcomes Strategic Investment from Advisors
Via ACCESS Newswire
IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs
Via ACCESS Newswire
IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program
Via ACCESS Newswire
IGC Pharma Reports Third Quarter Fiscal 2025 Results
Via ACCESS Newswire
IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby(TM)
Via ACCESS Newswire
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health
Via ACCESS Newswire
IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances
Via ACCESS Newswire
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences
Via ACCESS Newswire
IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida
Via ACCESS Newswire
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock. Raising P/T to $4.25"
Via ACCESS Newswire
IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy
Via ACCESSWIRE
IGC Pharma Advances IGC-AD1 as a Potential Alzheimer's Therapy Addressing Cognitive Impairment and Underlying Disease Pathology
Via ACCESSWIRE
IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the “Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results”
Via ACCESS Newswire
IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection
Via ACCESS Newswire
IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and 'Renew' - Targeting the Multi-Billion-Dollar Anti-Aging Market
Via ACCESS Newswire
IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer's Disease
Via ACCESS Newswire
IGC Pharma Appoints Former Virginia Governor Terry McAuliffe as Strategic Advisor
Via ACCESS Newswire
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets
Via ACCESSWIRE
IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025
Via ACCESSWIRE
Cannabinoid Drug For Agitation In Alzheimer's Yields Cognitive Improvements In Clinical Trial
Via Benzinga
IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment
From IGC Pharma, Inc.
Via Business Wire
IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer’s Pipeline
Via ACCESSWIRE
IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer’s and Weight Loss Therapies
Via ACCESSWIRE

Frequently Asked Questions

Is IGC Pharma, Inc. Common Stock publicly traded?
Yes, IGC Pharma, Inc. Common Stock is publicly traded.
What exchange does IGC Pharma, Inc. Common Stock trade on?
IGC Pharma, Inc. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for IGC Pharma, Inc. Common Stock?
The ticker symbol for IGC Pharma, Inc. Common Stock is IGC on the New York Stock Exchange
What is the current price of IGC Pharma, Inc. Common Stock?
The current price of IGC Pharma, Inc. Common Stock is 0.2993
When was IGC Pharma, Inc. Common Stock last traded?
The last trade of IGC Pharma, Inc. Common Stock was at 05/16/25 08:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.